Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.52 |
| ▸ | SPR | P35270 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586112 | 0.84 | HCRTR1 (0.52) | HCRTR2HCRTR1SPRLMNATSHR | |
| SCHEMBL652371 | 0.75 | PARP1 (0.49) | SPR | |
| SCHEMBL7689008 | 0.75 | PARP1 (0.49) | SPR | |
| SCHEMBL3572550 | 0.75 | NR1H2 (0.45) | SPRRECQL | |
| SCHEMBL3572552 | 0.75 | NR1H2 (0.45) | SPRRECQL | |
| SCHEMBL652372 | 0.74 | SPR (0.41) | SPR | |
| SCHEMBL18711487 | 0.72 | NR1H2 (0.45) | SPRRECQL | |
| SCHEMBL1671500 | 0.72 | CHRNA4 (0.63) | HCRTR2HCRTR1TSHRRECQL | |
| SCHEMBL25325855 | 0.71 | RORC (0.47) | LMNATSHRRECQL | |
| SCHEMBL18701818 | 0.71 | NR1H2 (0.44) | SPRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2491034-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-18 | — | — | EP | disclosed |
| EP-2491034-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885SPR 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.